Disparities in Early Lecanemab Uptake Among US Medicare Beneficiaries
This cross-sectional study examines lecanemeb update among Medicare fee-for-service beneficiaries with Alzheimer disease or mild cognitive impairment and evaluates whether there are disparities among potentially eligible patients.
Authors
- Utibe R. Essien (ORCID: https://orcid.org/0000-0002-4494-5028)
- John N. Mafi (ORCID: https://orcid.org/0000-0002-0322-7636)
- Catherine A. Sarkisian (ORCID: https://orcid.org/0000-0003-2768-2323)
- Jeffrey M. Souza
- Cheryl L. Damberg (ORCID: https://orcid.org/0000-0001-8169-9420)
- Bruce E. Landon (ORCID: https://orcid.org/0000-0003-4912-0647)
- Feng Zhou (ORCID: https://orcid.org/0000-0001-8683-9621)
Institutions
- RAND Corporation (US)
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- University of California, Los Angeles (US)
- Geriatric Research Education and Clinical Center (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-05-15
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.11711
- Citations
- 6
- Primary Topic
- Economic and Financial Impacts of Cancer
- Type
- article
- Field-Weighted Citation Impact
- 18.79